New Heart Failure Diagnoses Among Patients Hospitalized for COVID-19

Álvarez‐García, Jesús; Jaladanki, Suraj; Rivas‐Lasarte, Mercedes; Cagliostro, Matthew; Gupta, Arjun; Joshi, Aditya; Ting, Peter; Mitter, Sumeet S.; Bagiella, Emilia; Mancini, Donna

doi:10.1016/j.jacc.2021.03.006

Cited by 38 publications

(36 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a single-center analysis of hospitalized (critically ill and non-critically ill) COVID-19 patients, 37 were identified as having de novo HF, eight of whom had no prior cardiovascular disease or known risk factors. [8] The point prevalence of de novo HF in our cohort was >8-fold higher than that observed in that study (5.0% vs. 0.6%), likely related to the higher overall risk of our exclusively ICU-based population. Nevertheless, we also observed that many de novo HF patients had no known prior cardiovascular disease or risk factors.…”

Section: Discussioncontrasting

confidence: 73%

Epidemiology of Acute Heart Failure in Critically Ill Patients With COVID-19: An Analysis From the Critical Care Cardiology Trials Network

Berg

Alviar

Bhatt

et al. 2022

Journal of Cardiac Failure

View full text Add to dashboard Cite

Background Acute heart failure (HF) is an important complication of coronavirus disease 2019 (COVID-19) and has been hypothesized to relate to inflammatory activation. Methods We evaluated consecutive intensive care unit (ICU) admissions for COVID-19 across 6 centers in the Critical Care Cardiology Trials Network, identifying patients with vs. without acute HF. Acute HF was sub-classified as " de novo " vs. "acute-on-chronic" based on the absence or presence of prior HF. Clinical features, biomarker profiles, and outcomes were compared. Results Among 901 COVID-19 ICU admissions, 80 (8.9%) had acute HF, including 18 (2.0%) with classic cardiogenic shock (CS) and 37 (4.1%) with vasodilatory CS. The majority (n=45) were de novo HF presentations. Compared to patients without acute HF, those with acute HF had higher cardiac troponin (cTn) and natriuretic peptides, and similar inflammatory biomarkers; patients with de novo HF had the highest cTn. Notably, among critically ill patients with COVID-19, illness severity (median SOFA, 8 [IQR, 5-10] vs. 6 [ 4 -9]; p=0.025) and mortality (43.8% vs. 32.4%; p=0.040) were modestly higher in patients with vs. without acute HF. Conclusions Among critically ill COVID-19 patients, acute HF is distinguished more by biomarkers of myocardial injury and hemodynamic stress than by biomarkers of inflammation.

show abstract

Section: Discussioncontrasting

confidence: 73%

Epidemiology of Acute Heart Failure in Critically Ill Patients With COVID-19: An Analysis From the Critical Care Cardiology Trials Network

Berg

Alviar

Bhatt

et al. 2022

Journal of Cardiac Failure

View full text Add to dashboard Cite

show abstract

“…Acute HF was found to be a possible consequence of COVID-19, with a dramatic impact on mortality ( 26 ). During COVID-19 hospitalization, about one-third of patients with previous HF had an acute decompensation of HF ( 27 ); however, acute HF can be developed not only as a decompensation of chronic HF but also as a new-onset HF ( 128 ) ( Table 2 ). In an Italian multicenter study, acute HF occurred in 9.1% of patients during hospitalization for COVID-19, and almost half of them were “ de-novo ” HF in patients with no HF history ( 27 ).…”

Section: Heart Failure As a Consequence Of Covid-19mentioning

confidence: 99%

“…In an Italian multicenter study, acute HF occurred in 9.1% of patients during hospitalization for COVID-19, and almost half of them were “ de-novo ” HF in patients with no HF history ( 27 ). Among 3,080 consecutive patients with confirmed COVID-19 infection hospitalized in a tertiary center in Madrid (Spain), 2.5% of patients were diagnosed with acute HF and suffered from significantly higher mortality as compared with patients without HF(46.8 vs. 19.7%; p < 0.001) ( 128 ). Arrhythmias during hospital admission and chronic HF were the main predictors of acute HF; however, 77.9% of acute HF did not have a previous history of HF ( 128 ).…”

Section: Heart Failure As a Consequence Of Covid-19mentioning

confidence: 99%

COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae

Italia

Tomasoni

Bisegna

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

A close and intriguing relationship has been suggested between heart failure (HF) and coronavirus disease 2019 (COVID-19). First, COVID-19 pandemic represented a global public health emergency in the last year and had a catastrophic impact on health systems worldwide. Several studies showed a reduction in HF hospitalizations, ranging from 30 to 66% in different countries and leading to a subsequent increase in HF mortality. Second, pre-existing HF is a risk factor for a more severe clinical course of COVID-19 and an independent predictor of in-hospital mortality. Third, patients hospitalized for COVID-19 may develop both an acute decompensation of chronic HF and de-novo HF as a consequence of myocardial injury and cardiovascular (CV) complications. Myocardial injury occurred in at least 10% of unselected COVID-19 cases and up to 41% in critically ill patients or in those with concomitant CV comorbidities. Few cases of COVID-19-related acute myocarditis, presenting with severe reduction in the left ventricular (LV) ejection fraction and peculiar histopathological findings, were described. However, recent data suggested that COVID-19 may be associated with both systolic and diastolic LV dysfunction, with LV diastolic impairment, pulmonary hypertension, and right ventricular dysfunction representing the most frequent findings in echocardiographic studies. An overview of available data and the potential mechanisms behind myocardial injury, possibly leading to HF, will be presented in this review. Beyond the acute phase, HF as a possible long-term consequence of cardiac involvement in COVID-19 patients has been supposed and need to be investigated yet.

show abstract

“…In an adjunct study of the same 6439 patients hospitalized with COVID-19 in New York City, only 37 (0.6%) were discharged with a new diagnosis of HF. 49 , 52 Of these, 13 presented with shock (cardiogenic (n=4), septic (n=6), mixed (n=3)) and 5 patients presented with acute coronary syndrome. Notably, only eight patients had neither CV disease nor any CV risk factors, whereas 14 had a history of overt CV disease, and the other 15 had one or more risk factors that could have predisposed to the development of HF.…”

Section: Recognition Of Acute Heart Failure In Patients With Covid-19mentioning

confidence: 99%

Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America

Bhatt

Adler

Albert

et al. 2022

Journal of Cardiac Failure

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

New Heart Failure Diagnoses Among Patients Hospitalized for COVID-19

Cited by 38 publications

References 5 publications

Epidemiology of Acute Heart Failure in Critically Ill Patients With COVID-19: An Analysis From the Critical Care Cardiology Trials Network

Epidemiology of Acute Heart Failure in Critically Ill Patients With COVID-19: An Analysis From the Critical Care Cardiology Trials Network

COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae

Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America

Contact Info

Product

Resources

About